4 Aug 2023 • A study aimed to investigate whether using sodium-glucose cotransporter-2 (SGLT2) inhibitors as add-on to metformin is associated with the risk of fractures compared to using dipeptidyl peptidase-4 (DPP-4) inhibitors.

• The researchers selected patients aged 18 years and older who had a first-ever prescription for either a DPP-4 inhibitor or an SGLT2 inhibitor as add-on to metformin.
• The study included 13,807 SGLT2 inhibitor users and 28,524 DPP-4 inhibitor users. The results showed that the risk of any fracture with current SGLT2 inhibitor use was similar to current DPP-4 inhibitor use.

There was no significant difference in the risk of major osteoporotic fractures (MOFs) or fractures at any specific MOF site between the two groups. The duration of SGLT2 inhibitor use, specific SGLT2 inhibitor agents, and stratification by sex and age did not show any association with fracture risk either.

In conclusion, the use of SGLT2 inhibitors as add-on to metformin was not associated with an increased risk of any fracture, MOFs, or fractures at individual MOF sites when compared to the use of DPP-4 inhibitors.

Source: Diabetes, Obesity & Metabolism | Read full story